The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Neuralink's brain-computer interface will be tested in Canada, with Toronto's University Health System seeking patients for ...

Specific ancient viral DNA sequences in the human genome are linked to genetic risk for multiple sclerosis and amyotrophic ...

The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...

The trial will involve both single and multiple-ascending doses of SUDO-550 being given to healthy volunteers.

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.

MRI is a diagnostic test that doctors use to diagnose and track the progress of amyotrophic lateral sclerosis (ALS). ALS is a progressive disease that damages nerve cells in the brain and spinal cord.

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Fintel reports that on December 2, 2024, D. Boral Capital initiated coverage of MediciNova (NasdaqGM:MNOV) with a Buy ...